1Q Health Group Expands with Acquisition of German CRO VivaCell Biotechnology

  • 1Q Health Group has acquired VivaCell Biotechnology, a German CRO with over 20 years of expertise.

1Q Health Group, a European CDMO, has acquired VivaCell Biotechnology, a contract research organisation based in Germany. The acquisition supports the group’s aim to become a leading provider of premium pharmaceuticals and food supplements across Europe.

VivaCell brings more than two decades of experience in conducting in vitro and in vivo studies to test and develop products in sectors such as cosmetics, nutraceuticals, pharmaceuticals, probiotics, and natural products. The company offers services that help clients demonstrate the health benefits and efficacy of their products.

The acquisition adds to 1Q Health Group’s recent growth, following the earlier inclusion of ABJ alive in 2024 and HKS health solutions in 2025. The group was established by Nord Holding to create a comprehensive European platform for contract manufacturing and related services.

Experience the future of contract manufacturing

Join us at CDMO Live, 7-8 May 2025 in Rotterdam for an exclusive live event dedicated to contract manufacturing partnerships. Apply for your ticket.

Sign up to our free weekly newsletter for all the latest contract manufacturing news.  Register here

Who do you rate?
Recommend a Supplier

Help us find the most innovative and trusted suppliers in Pharma and Biotech.